IL6 and head and neck squamous cell carcinoma: As we were able to identify a subgroup of patients with adverse stimulation of MCP-1, IFN-γ and IL-6, and the increased levels of the three cytokines emerged as biomarkers for rather poor outcome, we reached the aim of this study by determining deviating effects of pembrolizumab, docetaxel and cisplatin on HNSCC and their cytokine release ex vivo.